1, Cinda Bio (HK 180 1): The company's main products are PD- 1 antibody cindizumab (IBI-308), bevacizumab (Avastin) biological analog IBI-305, and rituximab (rituximab).
2. Baekje Shenzhou (HK6 160): Baekje Shenzhou Co., Ltd. was established on 20 10/October 28th, and is a company mainly engaged in biopharmaceutical business. The company is mainly engaged in the research, development, production and sales of innovative molecular targeting and immune tumor drugs for cancer treatment.
3. Hengrui Pharma (600276): The company is one of the largest R&D and production bases of anti-tumor drugs, surgical drugs and contrast agents in China. The company's products cover many fields, such as anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and so on.
4. Junshi Bio (HK1877): 20181217, Yi Tuo (commonly known as "Tripril Monoclonal Antibody", project code "JS00 1") was approved for listing by NMPA.
The above is the sharing of PD 1 drug listed companies, hoping to help.